Differences in Lipid Measurements by Antiretroviral Regimen Exposure in Cohorts from Asia and Australia
Table 2
Number and frequency of total cholesterol measurements by type of regimen and cohort.
cART Regimen
AHOD No. of patients*
AHOD median (range) no. of measurements per patient
AHOD no. (%) of measurements
TAHOD no. of patients*
TAHOD median (range) no. of measurements per patient
TAHOD no. (%) of measurements
NRTIs (+TDF) + NVP
122
2 (1–6)
247 (10.8)
70
1 (1–4)
108 (1.9)
NRTIs (+TDF) + EFV
131
2 (1–4)
245 (10.7)
90
1 (1–4)
147 (2.6)
NRTIs + NVP
155
2 (1–6)
342 (14.9)
696
1 (1–8)
1157 (20.6)
NRTIs + EFV
97
2 (1–4)
211 (9.2)
684
2 (1–10)
1487 (26.5)
NRTIs (+TDF) + PI (+ATV)
140
1 (1–5)
266 (11.6)
20
1 (1–4)
28 (0.5)
NRTIs (+TDF) + PI
187
2 (1–7)
410 (17.9)
137
3 (1–6)
367 (6.5)
NRTIs + PI (+ATV)
78
2 (1–5)
178 (7.7)
232
3 (1–6)
610 (10.9)
NRTIs + PI
184
2 (1–6)
396 (17.2)
620
3 (1–12)
1698 (30.3)
Total
1094
2295 (100)
2548
5602 (100)
*Each patient could contribute to more than one regimen. AHOD: Australian HIV Observational Database; ATV: Atazanavir; EFV: Efavirenz; NNRTI: non- nucleoside reverse transcriptase inhibitors; NRTIs: nucleoside reverse transcriptase inhibitors; NVP: nevirapine; PI: protease inhibitor; TAHOD: TREAT Asia HIV Observational Database; TDF: tenofovir. Key. NRTIs are TDF based (NRTIs + TDF) or not (NRTIs) and PI as ATV based (PI + ATV) or not (PI).
